The results of liver transplantation in a total of 540 patients from four centers in the United States and Western Europe have been collated. Twenty‐five per cent of all transplants were performed for neoplastic disease. One– and 3–year survivals for this group were approximately 26 and 12% overall, and survival differed little for patients transplanted before and after January 1, 1980. Among the 44% of patients transplanted for endstage cirrhosis, 3–year survival was lowest for patients with alcoholic cirrhosis (20%). Three‐year survival was greater for patients with nonalcoholic cirrhosis (29% overall), did not differ markedly among the various subtypes, and was greater for patients transplanted after January 1, 1980 (42%), as compared with before (22%). Patients with biliary atresia, sclerosing cholangitis, and metabolic and miscellaneous disorders constituted the remaining 30% of patients; 3–year survival varied from about 20 to 44% overall for the various subgroups, with a consistent trend toward improved survival among patients transplanted after January 1, 1980. The use of cyclosporin may not wholly explain this improved survival among more recently transplanted patients. Quality of life for transplant recipients surviving at least 3 months, as judged by a limited amount of data regarding time‐in‐hospital and functional status, appears to be good.
Hepatology – Wiley
Published: Jan 1, 1984
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera